Pier Capital LLC boosted its holdings in OraSure Technologies, Inc. (NASDAQ:OSUR) by 39.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 360,089 shares of the medical instruments supplier’s stock after purchasing an additional 101,459 shares during the quarter. OraSure Technologies comprises approximately 1.2% of Pier Capital LLC’s portfolio, making the stock its 21st biggest position. Pier Capital LLC owned approximately 0.59% of OraSure Technologies worth $6,791,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in OSUR. Fred Alger Management Inc. acquired a new position in OraSure Technologies in the fourth quarter valued at approximately $20,415,000. Millennium Management LLC lifted its stake in OraSure Technologies by 87.9% in the fourth quarter. Millennium Management LLC now owns 1,624,216 shares of the medical instruments supplier’s stock valued at $30,633,000 after buying an additional 759,958 shares during the last quarter. Emerald Advisers Inc. PA purchased a new stake in OraSure Technologies in the fourth quarter valued at approximately $12,518,000. Fuller & Thaler Asset Management Inc. lifted its stake in OraSure Technologies by 175.6% in the third quarter. Fuller & Thaler Asset Management Inc. now owns 898,397 shares of the medical instruments supplier’s stock valued at $20,214,000 after buying an additional 572,397 shares during the last quarter. Finally, SG Capital Management LLC purchased a new stake in OraSure Technologies in the third quarter valued at approximately $9,205,000. 93.67% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Brian Smith sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $17.97, for a total transaction of $359,400.00. Following the completion of the sale, the executive vice president now owns 28,075 shares in the company, valued at $504,507.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen S. Phd Tang sold 23,333 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $17.97, for a total value of $419,294.01. Following the sale, the director now owns 59,749 shares of the company’s stock, valued at approximately $1,073,689.53. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.
Shares of OraSure Technologies stock opened at $18.06 on Monday. OraSure Technologies, Inc. has a 52 week low of $10.75 and a 52 week high of $23.01. The firm has a market capitalization of $1,101.06, a P/E ratio of 35.41, a price-to-earnings-growth ratio of 5.35 and a beta of 1.60.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. The company had revenue of $52.00 million during the quarter, compared to analysts’ expectations of $50.20 million. During the same quarter in the previous year, the business earned $0.13 earnings per share. The firm’s revenue for the quarter was up 46.5% on a year-over-year basis. analysts expect that OraSure Technologies, Inc. will post 0.27 earnings per share for the current fiscal year.
OSUR has been the subject of a number of research reports. Canaccord Genuity reiterated a “buy” rating and issued a $24.00 price objective on shares of OraSure Technologies in a research note on Friday, February 2nd. BidaskClub upgraded OraSure Technologies from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research note on Friday, February 9th. Finally, ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Friday, March 2nd. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. OraSure Technologies presently has an average rating of “Buy” and an average price target of $22.25.
TRADEMARK VIOLATION NOTICE: This article was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://ledgergazette.com/2018/03/19/orasure-technologies-inc-osur-shares-bought-by-pier-capital-llc.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.